Leptin in common obesity and associated disorders of metabolism

Journal of Endocrinology

Volumn 223, Issue 1, 2014, Pages T71-T81

  DePaoli, Alex M ^a  

^a NGM Biopharmaceuticals   (United States)

Author keywords

Leptin; Leptin resistance; Lipodystrophy; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity; Recombinant leptin; Type 2 diabetes

Indexed keywords

ADIPOCYTOKINE; CARBOHYDRATE; LIPID; PRAMLINTIDE; RECOMBINANT LEPTIN; AMYLIN; ANTIDIABETIC AGENT; LEPTIN;

ARTICLE; BODY COMPOSITION; BODY WEIGHT; CARBOHYDRATE METABOLISM; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; FEEDING BEHAVIOR; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LEPTIN DEFICIENCY; LIPID METABOLISM; LIPODYSTROPHY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT REDUCTION; ANIMAL; DIABETES MELLITUS, TYPE 2; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; ISLET AMYLOID POLYPEPTIDE; LEPTIN; LIPODYSTROPHY; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; TREATMENT OUTCOME;

EID: 84907195705     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-14-0258     Document Type: Article

References (58)

1. Bahary N, Siegel DA, Walsh J, Zhang Y, Leopold L, Leibel R, Proenca R & Friedman JM 1993 Microdissection of proximal mouse chromosome 6: identification of RFLPs tightly linked to the ob mutation. Mammalian Genome 4 511-515. (doi:10.1007/BF00364786)
2. Bartness TJ 2001 North American Association for the Study of Obesity annual meeting. IDrugs: the Investigational Drugs Journal 4 41-43.
3. Brook RD, Bard RL, Bodary PF, Eitzman DT, Rajagopalan S, Sun Y & DePaoli AM 2007 Blood pressure and vascular effects of leptin in humans. Metabolic Syndrome and Related Disorders 5 270-274. (doi:10.1089/met.2006.0023)
4. Canavan B, Salem RO, Schurgin S, Koutkia P, Lipinska I, Laposata M & Grinspoon S 2005 Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. Journal of Clinical Endocrinology and Metabolism 90 5779-5785. (doi:10.1210/jc.2005-0780)
5. Chan JL, Heist K, DePaoli AM, Veldhuis JD&Mantzoros CS 2003 The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. Journal of Clinical Investigation 111 1409-1421. (doi:10.1172/JCI200317490)
6. Chan JL, Bullen J, Stoyneva V, DePaoli AM, Addy C&Mantzoros CS 2005 Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess. Journal of Clinical Endocrinology and Metabolism 90 1618-1624. (doi:10.1210/jc.2004-1921)
7. Chan JL, Roth JD&Weyer C 2009 It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development. Journal of Investigative Medicine 57 777-783. (doi:10.231/JIM.0b013e3181b91911)
8. Chou K&Perry CM 2013 Metreleptin: first global approval. Drugs 73 989-997. (doi:10.1007/s40265-013-0074-7)
9. Cochran E, Young JR, Sebring N, DePaoli A, Oral EA&Gorden P 2004 Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. Journal of Clinical Endocrinology and Metabolism 89 1548-1554. (doi:10.1210/jc.2003-031952)
10. Coleman DL 1973 Effects of parabiosis of obese with diabetes and normal mice. Diabetologia 9 294-298. (doi:10.1007/BF01221857)
11. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL et al. 1996 Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine 334 292-295. (doi:10.1056/NEJM199602013340503)
12. El-Haschimi K, Pierroz DD, Hileman SM, Bjørbaek C&Flier JS 2000 Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. Journal of Clinical Investigation 105 1827-1832. (doi:10.1172/JCI9842)
13. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jeff SA, Perna F, Fontana S et al. 2002 Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. Journal of Clinical Investigation 110 1093-1103. (doi:10.1172/JCI0215693)
14. FDA Leptin Advisory Panel 2013 In FDA Advisory Committee Meeting: Myalept (metreleptin). Ed E Coleman. Beltsville, MD, USA: Food and Drug Administration. (available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrinologicand-MetabolicDrugsAdvisoryCommittee/UCM379648.pdf).
15. Frederich RC, Hamann A, Anderson S, Löllmann B, Lowell BB&Flier JS 1995 Leptin levels reflect body lipid content in mice: evidence for dietinduced resistance to leptin action. Nature Medicine 1 1311-1314. (doi:10.1038/nm1295-1311)
16. Friedman JM, Leibel RL, Siegel DS, Walsh J&Bahary N 1991 Molecular mapping of the mouse ob mutation. Genomics 11 1054-1062. (doi:10.1016/0888-7543(91)90032-A)
17. Garg A 2011 Lipodystrophies: genetic and acquired body fat disorders. Journal of Clinical Endocrinology and Metabolism 96 3313-3325. (doi:10.1210/jc.2011-1159)
18. Gavrila A, Chan JL, Miller LC, Heist K, Yiannakouris N&Mantzoros CS 2005 Circulating melanin-concentrating hormone, agouti-related protein, and α-melanocyte-stimulating hormone levels in relation to body composition: alterations in response to food deprivation and recombinant human leptin administration. Journal of Clinical Endocrinology and Metabolism 90 1047-1054. (doi:10.1210/jc.2004-1124)
19. Hall JE, da Silva AA, do Carmo JM, Dubinion D, Hamza S, Munusamy S, Smith G&Stec DE 2010 Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. Journal of Biological Chemistry 285 17271-17276. (doi:10.1074/jbc.R110.113175)
20. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P et al. 1999 Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. Journal of the American Medical Association 282 1568-1575. (doi:10.1001/jama.282.16.1568)
21. Holden JH, Darga LL, Olson SM, Stettner DC, Ardito EA&Lucas CP 1992 Long-term follow-up of patients attending a combination very-low calorie diet and behaviour therapy weight loss programme. International Journal of Obesity and Related Metabolic Disorders 16 605-613.
22. Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, Farid AR, Smith F & Campfield LA 2000 Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. Journal of Clinical Endocrinology and Metabolism 85 4003-4009. (doi:10.1210/jcem.85.11.6955)
23. Hukshorn CJ, van Dielen FM, Buurman WA, Westerterp-Plantenga MS, Campbell LA&Saris WH 2002 The effect of pegylated recombinant human leptin (PED-OB) on weight loss and inflammatory status in obese subjects. International Journal of Obesity 26 504-509. (doi:10.1038/sj.ijo.0801952)
24. Hukshorn CJ, Westerterp-Plantenga MS&Saris WH 2003 Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men. American Journal of Clinical Nutrition 77 771-776.
25. Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, Kleiner DE&Gorden P 2005 Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41 753-760. (doi:10.1002/hep.20672)
26. Kalra SP 2009 Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation. Peptides 30 1957-1963. (doi:10.1016/j.peptides.2009.07.021)
27. Korner J, Conroy R, Febres G, McMahon DJ, Conwell I, Karmally W & Aronne LJ 2013 Randomized double-blind placebo-controlled study of leptin administration after gastric bypass. Obesity 21 951-956. (doi:10.1002/oby.20433)
28. Kusakabe T, Ebihara K, Sakai T, Miyamoto L, Aotani D, Yamamoto Y, Yamamoto-Kataoka S, Aizawa-Abe M, Fujikura J, Hosoda K et al. 2012 Amylin improves the effect of leptin on insulin sensitivity in leptinresistant diet-induced obese mice. American Journal of Physiology. Endocrinology and Metabolism 302 E924-E931. (doi:10.1152/ajpendo.00198.2011)
29. Liu AG, Smith SR, Fujioka K&Greenway FL 2013 The effect of leptin, caffeine/ephedrine, and their combination upon visceral fat mass and weight loss. Obesity 21 1991-1996. (doi:10.1002/oby.20416)
30. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW et al. 1998 Leptin regulates proinflammatory immune responses. FASEB Journal 12 57-65.
31. Magkos F, Brennan A, Sweeney L, Kang ES, Doweiko J, Karchmer AW & Mantzoros CS 2011 Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus infected lipoatrophic men treated with pioglitazone: a pilot study. Metabolism 60 1045-1049. (doi:10.1016/j.metabol.2010.10.002)
32. Mittendorfer B, Horowitz JF, DePaoli AM, McCamish MA, Patterson BW & Klein S 2011 Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes. Diabetes 60 1474-1477. (doi:10.2337/db10-1302)
33. Montague CT, Faroogi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA et al. 1997 Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 26 903-908.
34. Moon H-S, Matarese G, Brennan AM, Chamberland JP, Liu X, Fiorenza CG, Mylvaganam GH, Abanni L, Carbone F, Williams CJ et al. 2011 Efficacy of metreleptin in obese type II diabetics: cellular and molecular pathways underlying leptin tolerance. Diabetes 60 1647-1656. (doi:10.2337/db10-1791)
35. Mulligan K, Khatami H, Schwarz J-M, Sakkas GK, DePaoli AM, Tai VW, Wen MJ, Lee GA, Grunfeld C&Schambelan M 2009 The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. Journal of Clinical Endocrinology and Metabolism 94 1137-1144. (doi:10.1210/jc.2008-1588)
36. Myers MG, Heymsfield SB, Haft C, Kahn BB, Laughlin M, Leibel RL, Tschöp MH&Yanovski JA 2012 Defining clinical leptin resistance -challenges and opportunities of defining clinical leptin resistance. Cell Metabolism 15 150-156. (doi:10.1016/j.cmet.2012.01.002)
37. Nainggolan L 2014 Myalept (Metreleptin) approved for generalized lipodystrophy. Medscape Feb 25, 2014 (http://www.medscape.com/viewarticle/821056).
38. Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, Kern B, von Fluee M&Beglinger C 2012 Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obesity Surgery 22 740-748. (doi:10.1007/s11695-012-0622-3)
39. Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, Koda JE & Weyer C 2009 Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17 1736-1743. (doi:10.1038/oby.2009.184)
40. Rosenbaum M, Nicolson M, Hirsch J, Heymsfield SB, Gallagher D, Chu F & Leibel RL 1996 Effects of gender, body composition, and menopause on plasma concentrations of leptin. Journal of Clinical Endocrinology and Metabolism 81 3424-3427.
41. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE&Leibel R 2002 Low-dose leptin administration reverses effects of sustained weight reduction on energy expenditure and circulating concentrations of thyroid hormones. Journal of Clinical Endocrinology and Metabolism 87 2391-2394. (doi:10.1210/jcem.87.5.8628)
42. Rosenbaum M, Goldsmith R, Bloomfield D, Magnano A, Weimer L, Heymsfield S, Gallagher D, Mayer L, Murphy E&Leibel RL 2005 Lowdose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. Journal of Clinical Investigation 115 3578-3586. (doi:10.1172/JCI25977)
43. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG&Baron AD 2008 Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. PNAS 105 7257-7262. (doi:10.1073/pnas.0706473105)
44. Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, Kleiner DE&Gorden P 2013 The liver diseases of lipodystrophy: the long-term effect of leptin treatment. Journal of Hepatology 59 131-137. (doi:10.1016/j.jhep.2013.02.007)
45. Schoeller DA, Cella LK, Sinha MK&Caro JF 1997 Entrainment of the diurnal rhythm of plasma leptin to meal timing. Journal of Clinical Investigation 100 1882-1887. (doi:10.1172/JCI119717)
46. Schurgin S, Canavan B, Koutkia P, DePaoli AM&Grinspoon SJ 2004 Endocrine and metabolic effects of physiologic r-met HuLeptin administration during acute caloric deprivation in normal weight women. Journal of Clinical Endocrinology and Metabolism 89 5402-5409. (doi:10.1210/jc.2004-1102)
47. Schwenger KJ&Allard JP 2014 Clinical approaches to non-alcoholic fatty liver disease. World Journal of Gastroenterology 20 1712-1723. (doi:10.3748/wjg.v20.i7.1712)
48. Shetty GK, Matarese G, Magkos F, Moon H-S, Liu X, Brennan AM, Mylvaganam G, Sykoutri D, DePaoli AM&Mantzoros CS 2011 Leptin administration to overweight and obese subjects for six months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. European Journal of Endocrinology 165 249-254. (doi:10.1530/EJE-11-0252)
49. Simha V, Subramanyam L, Szczepaniak L, Quittner C, Adams-Huet B, Snell P&Garg A 2012 Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. Journal of Clinical Endocrinology and Metabolism 97 785-792. (doi:10.1210/jc.2011-2229)
50. Sinha MK, Ohannesian JP, Heiman ML, Kriauciunas A, Stephens TW, Magosin S, Marco C&Caro JF 1996 Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subject. Journal of Clinical Investigation 97 1344-1347. (doi:10.1172/JCI118551)
51. Trevaskis JL, Lei C, Koda JE, Weyer C, Parkes DG & Roth JD 2010 Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats. Obesity 18 21-26. (doi:10.1038/oby.2009.187)
52. Wadden TA, Considine RV, Foster GD, Anderson DA, Sarwer DB&Caro JS 1998 Short- and long-term changes in serum leptin in dieting obese women: effects of caloric restriction and weight loss. Journal of Clinical Endocrinology and Metabolism 83 214-218.
53. Wang MY, Chen L, Clark GO, Lee Y, Stevens RD, Ilkayeva OR, Wenner BR, Bain JR, Charron MJ, Newgard CB et al. 2010 Leptin therapy in insulindeficient type I diabetes. PNAS 107 4813-4819. (doi:10.1073/pnas.0909422107)
54. Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A & Mantzoros CS 2004 Recombinant human leptin in women with hypothalamic amenorrhea. New England Journal of Medicine 351 987-997. (doi:10.1056/NEJMoa040388)
55. Westerterp-Plantenga MS, Saris WH, Hukshorn CJ&Campfield LA 2001 Effects of weekly administration of pegylated recombinant human OB protein on appetite profile and energy metabolism in obese men. American Journal of Clinical Nutrition 74 426-434.
56. Wolsk E, Mygind H, Grøndahl TS, Pedersen BK&van Hall G 2011 The role of leptin in human lipid and glucose metabolism: the effects of acute recombinant human leptin infusion in young healthy males. American Journal of Clinical Nutrition 94 1533-1544. (doi:10.3945/ajcn.111.012260)
57. Zelissen PM, Stenlof K, Lean ME, Fogteloo J, Keulen ET, Wilding J, Finer N, Rössner S, Lawrence E, Fletcher C et al. 2005 Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes, Obesity & Metabolism 7 755-761. (doi:10.1111/j.1463-1326.2005.00468.x)
58. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L & Friedman JM 1994 Positional cloning of the mouse obese gene and its human homologue. Nature 372 425-432. (doi:10.1038/372425a0)